Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.
Status:
Completed
Trial end date:
2019-02-15
Target enrollment:
Participant gender:
Summary
This was a study of treatment with ruxolitinib in patients who presented with transfusion
dependent or independent anemia. Starting dose was 10 mg BID. This dose was maintained for
the first 12 weeks of the study and up-titrated thereafter unless the subject met criteria
for dose hold or dose reduction